Leukemia

Article	Citations
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms	1139
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms	950
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia	802
COVID-19 in persons with haematological cancers	328
MDM2 inhibition: an important step forward in cancer therapy	193
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus	182
Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis	177
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation	175
SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine “storm” and risk factor for damage of hematopoietic stem cells	165
Extracellular microvesicles/exosomes: discovery, disbelief, acceptance, and the future?	154
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis	146
Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances	145
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey	139
Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia	135
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments	120
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia	112
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis	106
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression	104
Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies	101
Molecular biology of Hodgkin lymphoma	100
Risk factors for death in 1859 subjects with COVID-19	96
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)	95
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms	94
Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking	93
Hematological features of persons with COVID-19	91

Advances in understanding of angioimmunoblastic T-cell lymphoma	84
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma	79
Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia	76
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network	75
A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies	73
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML	72
Therapeutic implications of menin inhibition in acute leukemias	72
Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia	72
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) In	70
Treatment and unmet needs in steroid-refractory acute graft-versus-host disease	70
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leuk	70
The Nlrp3 inflammasome as a “rising star” in studies of normal and malignant hematopoiesis	68
T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?	68
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials	67
Development of CAR-T cell therapies for multiple myeloma	67
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib	66
Response to mRNA vaccination for COVID-19 among patients with multiple myeloma	66
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab	65
COVID-19 in persons with chronic myeloid leukaemia	65
Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical deci	63
Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years	62
Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma	61
SHMT inhibition is effective and synergizes with methotrexate in T-cell acute lymphoblastic leukemia	60
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9	60
Base-edited CAR T cells for combinational therapy against T cell malignancies	60
Catch me if you can: how AML and its niche escape immunotherapy	60
Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia	59
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study	59
Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape	58
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment	58
Genome instability in multiple myeloma	58
Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)	57
Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network	56
Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors	56
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study	55
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views	54
A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells	54
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy	53
JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis	53
Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting	52
The WHO Classification of Haematolymphoid Tumours	52
Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia	52
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS	52
Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials	51
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, internation	51
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study	51
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study	51
NK-/T-cell lymphomas	51
Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells	51
An evidence that SARS-Cov-2/COVID-19 spike protein (SP) damages hematopoietic stem/progenitor cells in the mechanism of pyroptosis in Nlrp3 inflammasome-dependent manner	50

Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival	50
CXCR4 in Waldenström’s Macroglobulinema: chances and challenges	50
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial	50
Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial	49
New strategies to treat AML: novel insights into AML survival pathways and combination therapies	48
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia	47
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study	46
Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease	46
Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma	46
Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)	46
Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma	46
Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations	46
High-risk additional chromosomal abnormalities at low blast counts herald death by CML	46
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia	45
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631	45
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey	44
Defining the vulnerable patient with myeloma—a frailty position paper of the European Myeloma Network	44
Frequently asked questions regarding SARS-CoV-2 in cancer patients—recommendations for clinicians caring for patients with malignant diseases	44
Second cancer incidence in CLL patients receiving BTK inhibitors	44
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant	44
Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis	44
Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial	44
Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study	44
Current challenges and unmet medical needs in myelodysplastic syndromes	44
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab	44
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial	43
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma	42
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial	42
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis	42
HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions	41
Germline variants drive myelodysplastic syndrome in young adults	41
N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression	41
Decrease post-transplant relapse using donor-derived expanded NK-cells	41
Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progression	41
Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia	41
Mortality trends in multiple myeloma after the introduction of novel therapies in the United States	41
Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion	40
COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter	40
Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma	40
Clinical relevance of extracellular vesicles in hematological neoplasms: from liquid biopsy to cell biopsy	40
Treatment resistance in diffuse large B-cell lymphoma	39
Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing	39
Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)	39
Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial	39
Targeting nuclear import and export in hematological malignancies	39
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results	38
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial	38
Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study	38
High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance	38
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations	37
Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group	37
Complex landscape of alternative splicing in myeloid neoplasms	37
Folate metabolism: a re-emerging therapeutic target in haematological cancers	37
Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT	37
Imatinib is not a potent anti-SARS-CoV-2 drug	36
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms	36
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b	36
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA	36
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results	36
COVID-19 among fit patients with CLL treated with venetoclax-based combinations	35
Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection	35
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML	35
Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma	35
Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of th	35
Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia	34
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib	34
Two decades of targeted therapies in acute myeloid leukemia	34
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma	34
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia	34
Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiency	34
Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome	34
Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas	34
Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19	34
JAK2 unmutated erythrocytosis: current diagnostic approach and therapeutic views	34
Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations	34
H3K79me2/3 controls enhancer–promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells	33
Erdheim–Chester disease: a rapidly evolving disease model	33
Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL	33
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial	33
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study	33

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse	32
The mutagenic impact of melphalan in multiple myeloma	32
Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL children	32
Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs	32
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE	32
Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways	32
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses	31
Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis	31
AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome	31
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients	31
Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer	31
Comparison of efficacy and health-related quality of life of first-line haploidentical hematopoietic stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive thera	31
Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation	30
Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia	30
Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy	30
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma	30
Risk of infections in patients with myeloproliferative neoplasms—a population-based cohort study of 8363 patients	30
Impact of Covid-19 on the treatment of acute myeloid leukemia	30
Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets	30
The KMT2A recombinome of acute leukemias in 2023	29
The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma	29
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma	29
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia	29
RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators	29
Cancer increases risk of in-hospital death from COVID-19 in persons <65 years and those not in complete remission	29
A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis	29
Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia	28
Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease	28
Adipocytes in hematopoiesis and acute leukemia: friends, enemies, or innocent bystanders?	28
Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response	28
Leukemia-induced dysfunctional TIM-3+CD4+ bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients	28
Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia	28
Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears	28
Pediatric MDS and bone marrow failure-associated germline mutations in SAMD9 and SAMD9L impair multiple pathways in primary hematopoietic cells	28
Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia	28
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis	28
Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis	27
Current status and future perspectives in targeted therapy of NPM1-mutated AML	27
Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencing	27
SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders	27
MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance	27
Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma	27
Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma	27
Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms	27
Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy	27
Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic l	27
Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease	27
Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients	26
CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study	26
CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas	26
IL-6 trans-signaling promotes the expansion and anti-tumor activity of CAR T cells	26
Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia	26
Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders	26
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma	26
The long non-coding RNA CRNDE regulates growth of multiple myeloma cells via an effect on IL6 signalling	26
Multiple myeloma and COVID-19	26
Regional BCG vaccination policy in former East- and West Germany may impact on both severity of SARS-CoV-2 and incidence of childhood leukemia	25
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines	25
Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma	25
Targeting an adenosine-mediated “don’t eat me signal” augments anti-lymphoma immunity by anti-CD20 monoclonal antibody	25
EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia	25
Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice	25
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis	25
TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition	25
Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo	25
KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements	24
Selective elimination of immunosuppressive T cells in patients with multiple myeloma	24
Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma	24
SARS-CoV-2 antibody responses in patients with acute leukaemia	24
Frequent mutations in the amino-terminal domain of BCL7A impair its tumor suppressor role in DLBCL	24
Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL	24
Diverse kinase alterations and myeloid-associated mutations in adult histiocytosis	24
Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research	24
Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990–2015	24
Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study	24
EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia	24
Hematopoietic stem and progenitor cell signaling in the niche	24
Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL	24
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study	24
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era	23
Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells	23
IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction—a retrospective propensity score analysis	23
Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial	23
Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration	23
CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report	23
Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)	23
A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients	23
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL	23
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML	23
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies	23
Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)	23
SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia	23
Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial	22
Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission	22
Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies	22